<DOC>
	<DOCNO>NCT01094392</DOCNO>
	<brief_summary>Asparaginase important drug treatment childhood leukemia . One rare severe side effect treatment thrombosis outside central nervous system . The aim study investigate describe influence coagulation parameter prolong treatment asparaginase . Hopefully knowledge help foresee risk thrombosis thus make possible prevent .</brief_summary>
	<brief_title>Hemostasis During Asparaginase Treatment Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Childhood ALL , eligible receive standard risk intermediate risk therapy describe protocol , write informed consent obtain No allergic reaction PEGasparaginase</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ALL</keyword>
	<keyword>PEG-asparaginase</keyword>
	<keyword>prolong treatment</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Central venous line</keyword>
	<keyword>Echocardiography</keyword>
</DOC>